Bustamante Eduardo Mariana, Keller Irene, Schuster Nathalie, Aebi Stefan, Jaggi Rolf
Department for BioMedical Research, University of Bern, Bern, Switzerland.
Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, USA.
J Genet Eng Biotechnol. 2023 Aug 8;21(1):81. doi: 10.1186/s43141-023-00541-6.
About one-third of patients with estrogen receptor alpha (ERα)-positive breast cancer have tumors which are progesterone receptor (PR) negative. PR is an important prognostic factor in breast cancer. Patients with ERα-positive/PR-negative tumors have shorter disease-free and overall survival than patients with ERα-positive/PR-positive tumors. New evidence has shown that progesterone (P4) has an anti-proliferative effect in ERα-positive breast cancer cells. However, the role of PR in breast cancer is only poorly understood.
We disrupted the PR gene (PGR) in ERα-positive/PR-positive T-47D cells using the CRISPR/Cas9 system. This resulted in cell pools we termed PR-low as P4 mediated effects were inhibited or blocked compared to control T-47D cells. We analyzed the gene expression profiles of PR-low and control T-47D cells in the absence of hormone and upon treatment with P4 alone or P4 together with estradiol (E2). Differentially expressed (DE) genes between experimental groups were characterized based on RNA-seq and Gene Ontology (GO) enrichment analyses.
The overall gene expression pattern was very similar between untreated PR-low and untreated control T-47D cells. More than 6000 genes were DE in control T-47D cells upon stimulation with P4 or P4 plus E2. When PR-low pools were subjected to the same hormonal treatment, up- or downregulation was either blocked/absent or consistently lower. We identified more than 3000 genes that were DE between hormone-treated PR-low and control T-47D cells. GO analysis revealed seven significantly enriched biological processes affected by PR and associated with G protein-coupled receptor (GPCR) pathways which have been described to support growth, invasiveness, and metastasis in breast cancer cells.
The present study provides new insights into the complex role of PR in ERα-positive/PR-positive breast cancer cells. Many of the genes affected by PR are part of central biological processes of tumorigenesis.
约三分之一雌激素受体α(ERα)阳性乳腺癌患者的肿瘤为孕激素受体(PR)阴性。PR是乳腺癌的一个重要预后因素。ERα阳性/PR阴性肿瘤患者的无病生存期和总生存期比ERα阳性/PR阳性肿瘤患者短。新证据表明,孕激素(P4)对ERα阳性乳腺癌细胞具有抗增殖作用。然而,PR在乳腺癌中的作用仍知之甚少。
我们使用CRISPR/Cas9系统在ERα阳性/PR阳性的T-47D细胞中破坏PR基因(PGR)。这产生了我们称为PR-low的细胞池,因为与对照T-47D细胞相比,P4介导的效应受到抑制或阻断。我们分析了在无激素以及单独用P4或P4与雌二醇(E2)联合处理时PR-low和对照T-47D细胞的基因表达谱。基于RNA测序和基因本体(GO)富集分析对实验组之间的差异表达(DE)基因进行了表征。
未处理的PR-low细胞和未处理的对照T-47D细胞之间的总体基因表达模式非常相似。在用P4或P4加E2刺激后,对照T-47D细胞中有超过6000个基因发生差异表达。当PR-low细胞池接受相同的激素处理时,上调或下调要么被阻断/不存在,要么始终较低。我们鉴定出在激素处理的PR-low细胞和对照T-47D细胞之间有超过3000个差异表达基因。GO分析揭示了七个受PR影响且与G蛋白偶联受体(GPCR)途径相关的显著富集的生物学过程,这些途径已被描述为支持乳腺癌细胞的生长、侵袭和转移。
本研究为PR在ERα阳性/PR阳性乳腺癌细胞中的复杂作用提供了新见解。许多受PR影响的基因是肿瘤发生核心生物学过程的一部分。